. 2016 Dec;359(3):471–481. doi: 10.1124/jpet.116.236547

TABLE 4 .

Effects on secondary measures following intranasal drug administration (PD analysis set)

Pairwise comparisons were assessed using the Wilcoxon signed-rank test.

Parameter	Statistic	PBO lactose  (n = 32)	PBO ELX  (n = 34)	OXY IR 15 mg (n = 32)	OXY IR 30 mg (n = 32)	ELX 100 mg (n = 32)	ELX 200 mg (n = 32)
Overall Drug Liking VAS
At 12 h	Mean (S.D.)	43.8 (16.8)	37.6 (22.9)	76.4 (25.3)	80.9 (22.8)	20.7 (26.9)	17.0 (26.7)
	Median	50.0	50.0	76.0	88.0	6.5	0.0
	P value^a	—	NS	***	***	*** ^{§§ ††† ‡‡‡}	*** ^{§§§ ††† ‡‡‡}
Take Drug Again VAS
At 12 h	Mean (S.D.)	6.6 (17.7)	7.0 (19.0)	78.4 (30.5)	81.4 (22.5)	15.3 (27.5)	9.4 (22.5)
	Median	0.0	0.0	94.0	94.0	0.0	0.0
	P value^b	—	NS	***	***	^{††† ‡‡‡}	^{††† ‡‡‡}
Bad Effects VAS
E_max	Mean (S.D.)	2.2 (8.8)	17.4 (25.0)	22.6 (28.2)	35.2 (35.0)	62.8 (38.7)	74.2 (32.0)
	Median	0.0	0.0	11.5	26.0	74.5	83.5
	P value^b	—	^*	^*	***	*** ^{§§§ ††† ‡‡}	*** ^{§§§ ††† ‡‡‡}
Pupil diameter
MPC	Mean (S.D.)	0.6 (0.5)	0.5 (0.5)	2.2 (0.8)	2.7 (0.8)	1.1 (0.6)	1.1 (0.6)
	Median	0.6	0.5	2.2	2.7	1.0	1.1
	P value^a	—	—	***	***	*** ^{§§§ ††† ‡‡‡}	*** ^{§§§ ††† ‡‡‡}

ELX, eluxadoline; LS, least squares; MPC, maximum pupil constriction; NS, not significant; OXY IR, oxycodone immediate release; PBO, placebo.

^{^a}

P values are for pairwise comparisons of LS mean differences between treatments.

^{^b}

P values are for pairwise comparisons of median differences between treatments. Both assessed using the Wilcoxon signed-rank test.

Significant versus PBO lactose (P < 0.05);***significant versus PBO lactose (P < 0.0001);^§§significant versus PBO ELX (P < 0.01); ^§§§significant versus PBO ELX (P < 0.0001); ^†††significant versus OXY IR 15 mg (P < 0.0001); ^‡‡significant versus OXY IR 30 mg (P < 0.01); ^‡‡‡significant versus OXY IR 30 mg (P < 0.0001).